Figure S7 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chengcai Liang,Yingnan Wang,Min Wang,Yanxing Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.23779490

2023-01-01

Abstract:Figure S7: TOPFLASH analysis of JUP in TRIM50 overexpressing versus control empty vector 293T cells.

What problem does this paper attempt to address?

Figure S6 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chengcai Liang,Yingnan Wang,Min Wang,Yanxing Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.23779496.v1

2023-01-01

Abstract:Figure S6: Immunoblotting analysis of JUP in TRIM50 overexpressing versus control empty vector MKN45 cells.
Figure S4 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chengcai Liang,Yingnan Wang,Min Wang,Yanxing Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.24229470.v1

2023-01-01

Abstract:Figure S4: The TRIM50 and JUP binding domain predicted by I-TASSER-MTD. Blue indicated TRIM50. Green indicated JUP. Purple highlighted the interaction sites in RING and PRY/SPRY domain.
Figure S2 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chengcai Liang,Yingnan Wang,Min Wang,Yanxing Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.23779511

2023-01-01

Abstract:Figure S2: Immunoblotting assay of TRIM50 expression in GC cells.
Figure S1 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chengcai Liang,Yingnan Wang,Min Wang,Yanxing Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.24229479.v1

2023-01-01

Abstract:Figure S1A: The expression of TRIM50 and UBE2QL1 in the Cancer Genome Atlas (TCGA) database. Figure S1B: The IHC score of Figure 1F.
Figure S3 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chaozhao Liang,Yingnan Wang,Min Wang,Y. Eugene Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.23779508.v1

2023-01-01

Abstract:Figure S3A: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 overexpressing (TRIM50) versus control empty vector (EV) MKN45 cells (n = 6 mice per group). Scale bar: 1 cm Figure S3B: MKN74 cells were transfected with lentiviruses expressing TRIM50 shRNA. A universal nonsilencing shRNA was used as a negative control (sh-NC). Whole-cell lysates were subjected to immunoblot analysis with TRIM50 antibody. Figure S3C: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 knockdown (TRIM50 sh-1/TRIM50 sh-2) versus control (TRIM50 sh-NC) MKN74 cells (n = 6 mice per group). Scale bar: 1 cm
TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Jiajia Hu,Runjie Huang,Chengcai Liang,Yingnan Wang,Min Wang,Yanxing Chen,Chenyi Wu,Jinling Zhang,Zekun Liu,Qi Zhao,Zexian Liu,Feng Wang,Shuqiang Yuan

DOI: https://doi.org/10.1158/1541-7786.MCR-23-0113

2023-01-01

Abstract:Gastric cancer is one of the most frequent cancers in the world. Emerging clinical data show that ubiquitination system disruptions are likely involved in carcinoma genesis and progression. However, the precise role of ubiquitin (Ub)-mediated control of oncogene products or tumor suppressors in gastric cancer is unknown. Tripartite motif-containing 50 (TRIM50), an E3 ligase, was discovered by high-output screening of ubiquitination-related genes in tissues from patients with gastric cancer to be among the ubiquitination-related enzymes whose expression was most downregulated in gastric cancer. With two different databases, we verified that TRIM50 expression was lower in tumor tissues relative to normal tissues. TRIM50 also suppressed gastric cancer cell growth and migration in vitro and in vivo. JUP, a transcription factor, was identified as a new TRIM50 ubiquitination target by MS and coimmunoprecipitation experiments. TRIM50 increases JUP K63-linked polyubiquitination mostly at the K57 site. We discovered that the K57 site is critical for JUP nuclear translocation by prediction with the iNuLoC website and further studies. Furthermore, ubiquitination of the K57 site limits JUP nuclear translocation, consequently inhibiting the MYC signaling pathway. These findings identify TRIM50 as a novel coordinator in gastric cancer cells, providing a potential target for the development of new gastric cancer treatment strategies. Implications: TRIM50 regulates gastric cancer tumor progression, and these study suggest TRIM50 as a new cancer target. [GRAPHICS] .
Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma

Lingyun Wu,Xin Yin,Kan Jiang,Jie Yin,Hao Yu,Lingling Yang,Chiyuan Ma,Senxiang Yan

DOI: https://doi.org/10.1002/cam4.4552

IF: 4.711

2022-01-01

Cancer Medicine

Abstract:Introduction TRIpartite motif (TRIM) proteins are important members of the Really Interesting New Gene-finger-containing E3 ubiquitin-conjugating enzyme and are involved in the progression of hepatocellular carcinoma (HCC). However, the diverse expression patterns of TRIMs and their roles in prognosis and immune infiltrates in HCC have yet to be analyzed. Materials Combined with previous research, we used an Oncomine database and the Human Protein Atlas to compare TRIM family genes' transcriptional levels between tumor samples and normal liver tissues, as verified by the Gene Expression Profiling Interactive Analysis database. We investigated the patient survival data of TRIMs from the Kaplan-Meier plotter database. Clinicopathologic characteristics associations and potential diagnostic and prognostic values were validated with clinical and expressional data collected from the cancer genome atlas. Results We identified TRIM28, TRIM37, TRIM45, and TRIM59 as high-priority members of the TRIMs family that modulates HCC. Low expression of TRIM28 was associated with shorter overall survival (OS) than high expression (log-rank p = 0.009). The same trend was identified for TRIM37 (p = 0.001), TRIM45 (p = 0.013), and TRIM59 (p = 0.011). Multivariate analysis indicated that the level of TRIM37 was a significant independent prognostic factor for both OS (p = 0.043) and progression-free interval (p = 0.044). We performed expression and mutation analysis and functional pathways and tumor immune infiltration analysis of the changes in TRIM factors. Conclusion These data suggested that TRIM28, TRIM37, TRIM45, and TRIM59 could serve as efficient prognostic biomarkers and therapeutic targets in HCC.
Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly

Chao Yuan,Yanli Liao,WenXia Si,Mi Huang,Duanzhuo Li,Fuqing Wang,Yi Quan,Xin Yu,Shengjie Liao

DOI: https://doi.org/10.1016/j.bbadis.2024.167533

Abstract:Endoplasmic reticulum-associated degradation (ERAD) serves as a crucial quality and quantity control system that removes misfolded or unassembled proteins from the Endoplasmic Reticulum (ER) through the cytoplasmic ubiquitin-proteasome system (UPS), which is critical for cell fate decision. ER stress arises when misfolded proteins accumulated within the ER lumen, potentially leading to cell death via proapoptotic unfolded protein response (UPR). UFD1 in associated with VCP-Npl4, is recognized as a key regulator of protein homeostasis in ERAD. However, the factors that control VCP complex assembly remain unclear. The study elucidates the function of Trim21, an E3 ubiquitin ligase, through its interaction with UFD1, facilitating K27-linkage ubiquitination of UFD1 and inhibiting its incorporation into the VCP complex. This results in the suppression of ERAD substrates degradation and the activation of a proapoptotic unfolded protein response in cancer cells. Additionally, Trim21 over-expression enhances ER stress response and promotes apoptosis upon expose to the ER inducer Tunicamycin. Notably, elevated Trim21 expression correlates with improved overall survival in various tumor types. Overall, the findings highlight the critical role of Trim21 in regulating ERAD progression and cell fate determination in cancer cells through modulation of VCP/Npl4/UFD1 complex assembly.
TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability

Jianguo Wang,Jing Ye,Rongqiang Liu,Chen Chen,Weixing Wang

DOI: https://doi.org/10.1186/s13062-024-00555-1

2024-11-09

Biology Direct

Abstract:The expression of TRIM47, a member of the TRIM protein and E3 ubiquitin ligase families, is elevated in various cancers, such as non-small cell lung cancer and colorectal cancer, and is linked to poor prognosis. This study aimed to investigate the role of TRIM47 in gastric cancer development. Using The Cancer Genome Atlas-Stomach Adenocarcinoma (TCGA-STAD) dataset and analysis of 20 patient samples from our center, TRIM47 was found to be significantly up-regulated in gastric cancer tissues and associated with advanced N-stage and poor prognosis. We constructed stable TRIM47 knockdown and overexpressing gastric cancer cell lines. CCK8, EDU, colony formation, wound healing, and Transwell tests were used to evaluate the effects on cell proliferation, invasion, and migration. The results showed that TRIM47 knockdown inhibited the proliferation, migration and invasion of gastric cancer cells, while TRIM47 overexpression promoted these behaviors. These results were further confirmed in vivo. In the mechanism part, we found that TRIM47 interacts with CYLD protein. Moreover, TRIM47 promotes K48-linked ubiquitination, leading to the degradation of CYLD by the proteasome, thereby activating the NF-κB pathway and regulating the biological behavior of gastric cancer cells. Taken together, our study demonstrated that TRIM47 is involved in the proliferation and metastasis of gastric cancer through the CYLD/NF-κB pathway.

biology
TRIM50 inhibits glycolysis and the malignant progression of gastric cancer by ubiquitinating PGK1

Chao Gu,Yiwen Xia,Chen Lu,Shengkui Qiu,Jihuan Wang,Lu Zhang,Jialun Lv,Tianlu Jiang,Lang Fang,Penghui Xu,Zetian Chen,Ying Li,Li Xie,Zekuan Xu,Bowen Li

DOI: https://doi.org/10.7150/ijbs.97091

2024-07-01

Abstract:Ubiquitination plays a pivotal regulatory role in tumor progression. Among the components of the ubiquitin-proteasome system (UPS), ubiquitin-protein ligase E3 has emerged as a key molecule. Nevertheless, the biological functions of E3 ubiquitin ligases and their potential mechanisms orchestrating glycolysis in gastric cancer (GC) remain to be elucidated. In this study, we conducted a comprehensive transcriptomic analysis to identify the core E3 ubiquitin ligases in GC, followed by extensive validation of the expression patterns and clinical significance of Tripartite motif-containing 50 (TRIM50) both in vitro and in vivo. Remarkably, we found that TRIM50 was downregulated in GC tissues, associated with malignant progression and poor patient survival. Functionally, overexpression of TRIM50 suppressed GC cell proliferation and indirectly mitigated the invasion and migration of GC cells by inhibiting the M2 polarization of tumor-associated macrophages (TAMs). Mechanistically, TRIM50 inhibited the glycolytic pathway by ubiquitinating Phosphoglycerate Kinase 1 (PGK1), thereby directly suppressing GC cell proliferation. Simultaneously, the reduction in lactate led to diminished M2 polarization of TAMs, indirectly inhibiting the invasion and migration of GC cells. Notably, the downregulation of TRIM50 in GC was mediated by the METTL3/YTHDF2 axis in an m6A-dependent manner. In our study, we definitively identified TRIM50 as a tumor suppressor gene (TSG) that effectively inhibits glycolysis and the malignant progression of GC by ubiquitinating PGK1, thus offering novel insights and promising targets for the diagnosis and treatment of GC.
TRIM50 Inhibits Proliferation and Metastasis of Gastric Cancer via Promoting β-Catenin Degradation

Rongzhou Li,Peng Xu,Xiaosheng Jin,Zhengchao Shi,Qingqing Zhang,Fangpeng Ye,Weilai Yu,Tingting Ji

DOI: https://doi.org/10.1155/2022/5936753

2022-08-22

Abstract:Background: Gastric cancer (GC) is a common malignancy with a poor prognosis. Tripartite motif-containing 50 (TRIM50) belongs to the TRIM family and is reported to be related to numerous cancers. This study aimed to investigate the function of TRIM50 in GC. Methods: Three microarray datasets (GSE13911, GSE79973, and GSE19826) containing GC and adjacent nontumor tissues were used for bioinformatics analysis to screen GC-related genes and assess the associations between GC development and TRIM50 expression. Then, TRIM50 expression in GC cells was detected at mRNA and protein levels. After TRIM50 was knockdown or overexpressed, the effect of TRIM50 on the proliferation and metastasis of GC cells was analyzed using Cell Counting Kit-8 (CCK-8), flow cytometry, scratch, and Transwell assays. The interaction between TRIM50 and β-catenin was analyzed. The expression of cell cycle-, migration-, invasion-, and Wnt/β-catenin signaling pathway-related proteins was detected by Western blot. Furthermore, we measured the role of TRIM50 overexpression on tumor growth as well as the Wnt/β-catenin signaling pathway in vivo. In addition, XAV939 (a WNT/β-catenin signaling pathway inhibitor) was used to clarify the mechanism of TRIM50 on GC. Results: Bioinformatics revealed that TRIM50 expression was decreased in GC samples and associated with GC development. In vitro study revealed that TRIM50 overexpression impeded the GC cell proliferation and metastasis, while TRIM50 knockdown presented the opposite results. In addition, TRIM50 interacted with β-catenin to induce the degradation of β-catenin. In in vivo assay, TRIM50 overexpression inhibited tumor growth and blocked the Wnt/β-catenin signaling pathway. In addition, TRIM50 knockdown-promoted cell proliferation and metastasis in GC cells were inverted by XAV939. Conclusion: TRIM50 overexpression may inhibit cell proliferation and metastasis in GC via β-catenin degradation, indicating that TRIM50 could be a target for the treatment of GC.
TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance

Xiaoxiao Ma,Shuqin Jia,Gangjian Wang,Min Liang,Ting Guo,Hong Du,Sisi Li,Xiaomei Li,Longtao Huangfu,Jianping Guo,Xiaofang Xing,Jiafu Ji

DOI: https://doi.org/10.1038/s41392-023-01450-3

IF: 39.3

2023-01-01

Signal Transduction and Targeted Therapy

Abstract:Immune checkpoint blockade (ICB) offers a new opportunity for treatment for gastric cancer (G.C.). Understanding the upstream regulation of immune checkpoints is crucial to further improve the efficacy of ICB therapy. Herein, using the CRISPR-Cas9-based genome-wide screening, we identified TRIM28 as one of the most significant regulators of PD-L1, a checkpoint protein, in G.C. cells. Mechanistically, TRIM28 directly binds to and stabilizes PD-L1 by inhibiting PD-L1 ubiquitination and promoting PD-L1 SUMOylation. Furthermore, TRIM28 facilitates K63 polyubiquitination of TBK1, activating TBK1-IRF1 and TBK1-mTOR pathways, resulting in enhanced PD-L1 transcription. It was found that TRIM28 was positively correlated with PD-L1 in G.C. cells. Moreover, high TRIM28 expression suggests poor survival in a cohort of 466 patients with G.C., and this observation is consistent while analyzing data from publicly available databases. Ectopic TRIM28 expression facilitated tumor growth, increased PD-L1 expression, and suppressed T cell activation in mice. Administration of the PD-L1 or TBK1 inhibitor significantly alleviated the TRIM28-induced tumor progression. Furthermore, combining the TBK1 inhibitor with CTLA4 immune checkpoint blockade has synergistic effects on G.C., and provides a novel strategy for G.C. therapy.
TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1

Shuier Zheng,Chenliang Zhou,Yonggang Wang,Hongtao Li,Yong Sun,Zan Shen

DOI: https://doi.org/10.1186/s13046-019-1504-5

2020-01-28

Abstract:Abstract Background Tripartite motif-containing proteins (TRIM) play a crucial role in carcinogenesis. Little attention has been focused on the possible functions of TRIM6 on carcinogenesis. Methods The expression levels of TRIM6 were assessed in colorectal cancer (CRC) samples. TRIM6 expression was knocked down in CRC cell lines, and subjected to Cell counting kit-8 (CCK-8), bromodeoxyuridine (BrdU) incorporation and cell cycle assays. Immunoprecipitation and proteomics analysis was performed to identify potential associated proteins of TRIM6. Results TRIM6 expression was up-regulated in CRC samples and TRIM6 expression may be an independent prognostic marker for CRC. Knocking down TRIM6 expression suppressed CRC cell proliferation, induced cell cycle arrested at G2/M phase and increased sensitivity to 5-fluorouracil and oxaliplatin. TIS21, an anti-proliferative protein involved in the regulation of G2/M arrest, was identified as an interaction partner of TRIM6. Moreover, CRC cells with TRIM6 overexpression showed decreased TIS21 protein stability. TIS21 ubiquitination was increased in CRC cells overexpressing TRIM6, but not in those overexpressing TRIM6 E3 catalytic mutant (C15A). Further, Lys5 was essential for TRIM6 mediated TIS21 ubiquitination. TIS21 overexpression reversed the induced effects of TRIM6 overexpression on CRC cell proliferation, and the levels of forkhead box M1 (FoxM1), phosphorylated FoxM1, Cyclin B1 and c-Myc. Thiostrepton, a specific inhibitor for FoxM1, was less effective in anti-proliferative activity against CRC cells with lower level of TRIM6 in vitro and in vivo. Conclusions Our study suggests that TRIM6 promotes the progression of CRC via TIS21/FoxM1.

oncology
TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation Via UPP.

Rongxin Shang,Jiakuan Chen,Yang Gao,Jijun Chen,Guoliang Han

DOI: https://doi.org/10.1155/2023/5899662

2023-01-01

Disease Markers

Abstract:Background:Currently, how to successfully control refractory and metastatic diseases remains a fundamental goal for clinicians to improve therapeutic effects for patients with non-small cell lung cancer (NSCLC). Several studies have discovered that TRIM58, a member of tripartite motif protein family, shows antitumor effect in multiple types of cancer. In this study, we aimed to further clarify the molecular regulatory network of TRIM58 and corresponding targets for NSCLC patients.Methods:TRIM58 expression in clinical tumor tissue samples and cancer cell lines was examined. Functional experiments including cellular invasion, cell metastasis, chemoresistance assay, and ubiquitination evaluation experiments were conducted to investigate the interaction between TRIM58 and ZEB1, which is a prime element of transcription factor network that controls epithelial-to-mesenchymal transition.Results:TRIM58 expression was characteristically decreased in NSCLC tumor tissues and cancer cell lines. Functional experiments demonstrated that TRIM58 suppression enhanced malignant biological behaviors including cellular survivability, migration, and invasion, as well as stem-like cellular phenotype of tumor cells. TRIM58 silencing also significantly enhanced the chemoresistance of NSCLC cells to chemoagents. TRIM58-ZEB1 interaction accelerated degradation of ZEB1 protein, thus further leading to the augment of tumor behaviors. Further detailed molecular experiments revealed that the interaction between TRIM58 and ZEB1 was mediated via ubiquitin-proteasome pathway (UPP).Conclusion:TRIM58 suppressed NSCLC through interacting with ZEB1 and promoting ZEB1 protein degradation via UPP. The present research sheds light on the interaction between TRIM58 and ZEB1, and TRIM58/ZEB1 axis might be the potential therapeutic targets of NSCLC.
STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer

Chengdong Huo,Yanmei Gu,Daijun Wang,Xiaoxia Zhang,Futian Tang,Bin Zhao,Tao Liu,Wenting He,Yumin Li

DOI: https://doi.org/10.1007/s00432-023-05307-8

2023-08-28

Journal of Cancer Research and Clinical Oncology

Abstract:PurposeTripartite motif-containing protein 21 (TRIM21) has E3 ubiquitin ligase activity and is involved in the regulation of various biological processes in vivo. TRIM21 has been found to have strong associations with various cancers. However, its role in gastric cancer is unclear.MethodsThe TCGA database was screened to obtain TRIM21 using WGCNA and PPI analyses. The TCGA database was used to evaluate the correlation of TRIM21 expression with patients’ clinical characteristics, prognosis, functional enrichment and immune cell infiltration. The role of TRIM21 in cell proliferation, apoptosis and invasion was verified by in vivo and in vitro assays. The UCSC and JASPAR databases were used to evaluate the regulatory role of STAT1 on TRIM21 transcription. Finally, dual-luciferase reporter assay was used to confirm the regulation of TRIM21 transcriptional activity by STAT1.ResultsAs a key gene, high expression of TRIM21 inhibited the gastric cancer growth and was significantly enriched in apoptosis, cell proliferation, and JAK/STAT signaling pathways. TRIM21 expression was positively correlated with a variety of TICs, including T cells, NK cells, and DCs. In vivo assays, TRIM21 inhibited functions in gastric cancer cell lines, including inhibition of proliferation and migration, and promotion of apoptosis. Database analysis and dual-luciferase reporter assay showed that STAT1 inhibited the transcriptional activity of TRIM21. In vivo assays confirmed that TRIM21 inhibited tumor growth, and STAT1 expression was negatively correlated with STAT1.ConclusionTRIM21 is a tumor-suppressive gene in gastric cancer, and its transcriptional activity is inhibited by STAT1.

oncology
Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition

Danxiang Chen,Jing Jiang,Wei Zhang,Xinlin Li,Qidong Ge,Xia Liu,Xujun Li

DOI: https://doi.org/10.1080/15384047.2024.2427410

2024-11-20

Cancer Biology & Therapy

Abstract:Background and Objectives Tripartite motif-containing protein 50 (TRIM50) is a recently discovered E3 ubiquitin ligase that participates in tumor progression. TRIM50 is overexpressed in many cancers, although few studies focused on TRIM50's role in breast cancer.

oncology
TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4

Qian Liang,Chaotao Tang,Mingyu Tang,Qingwei Zhang,Yunjie Gao,Zhizheng Ge

DOI: https://doi.org/10.1186/s13046-019-1143-x

2019-04-12

Abstract:<h3>Background</h3><p>Tripartite motif 47 (TRIM47), a member of the TRIM family proteins, plays a key role in many types of cancers including colorectal cancer (CRC). We found that levels of TRIM47 mRNA and protein were increased significantly in colorectal tumors compared with nontumor tissues and the increased levels were associated with advanced tumor stage and poor outcome.</p>

oncology
TRIM40 interacts with ROCK1 directly and inhibits colorectal cancer cell proliferation through the c-Myc/p21 axis

Fangyu Hu,Lingling Zhao,Junyu Wang,Xiaoying Li,Zixuan Xue,Yimeng Ma,Minghui Zheng,Chenglin Chen,Meiting Tong,Xiaohuan Guo,Hongyan Li,Honglei Jin,Qipeng Xie,Xiaodong Zhang,Chuanshu Huang,Haishan Huang

DOI: https://doi.org/10.1016/j.bbamcr.2024.119855

Abstract:Background: Colorectal cancer (CRC) is the most common malignancy of the digestive tract, and to date, morbidity and mortality rates remain high. While existing therapeutic methods have achieved certain effective outcomes, there are still many problems in treating this disease. Therefore, it is still urgent to constantly find new therapeutic targets in CRC that could lead to new therapeutics. Methods: Immunohistochemistry, Real-time PCR and Western Blot were employed to measure mRNA and protein levels of the target protein, respectively. The proliferation ability of CRC cells was evaluated using ATP assay, Soft agar assay, and nude mouse subcutaneous tumorigenesis assay. Protein Degradation Assay was conducted to determine protein degradation rate, while Ubiquitination assay was used to assess the ubiquitination modification level of target proteins. Immunoprecipitation assay was used to study protein interactions, and pull-down assay was employed to investigate direct interactions between proteins. Results: TRIM40 was significantly down-regulated in CRC tissues, with its expression levels positively correlating with disease prognosis. Using both in vitro and in vivo approaches, it was demonstrated that TRIM40 could significantly inhibit the proliferation of CRC cells. Molecular mechanism studies showed that TRIM40 directly binds to and ubiquitinates ROCK1 protein, accelerating its degradation and subsequently reducing the stability of c-Myc protein. This cascade of events results in the release of transcriptional inhibition of p21 by c-Myc, leading to increased p21 expression and G0/G1 phase arrest in CRC cells. Conclusion: This research suggests that TRIM40 could be a valuable therapeutic target for the treatment of CRC.
The E3 ubiquitin ligase TRIM17 promotes gastric cancer survival and progression via controlling BAX stability and antagonizing apoptosis

Jiajia Shen,Hang Yang,Xinran Qiao,Yang Chen,Liyun Zheng,Jingyu Lin,Jingyu Lang,Qiang Yu,Zhen Wang

DOI: https://doi.org/10.1038/s41418-023-01221-1

2023-09-11

Abstract:Tripartite motif 17 (TRIM17) belongs to a subfamily of the RING-type E3 ubiquitin ligases, and regulates several cellular processes and pathological conditions including cancer. However, its potential function in gastric cancer (GC) remains obscure. Here, we have found TRIM17 mRNA and protein levels are both upregulated in human GC compared with normal specimens, and TRIM17 upregulation indicates poor survival for GC patients. Functionally, TRIM17 was found to act as an oncogene by promoting the proliferation and survival of GC cell lines AGS and HGC-27. Mechanistically, TRIM17 acts to interact with BAX and promote its ubiquitination and proteasomal degradation, leading to a deficiency in BAX-dependent apoptosis in GC cells in the absence and presence of apoptosis stimuli. Moreover, TRIM17 and BAX expression levels are inversely correlated in human GC specimens. Our data thus suggest TRIM17 contributes to gastric cancer survival through regulating BAX protein stability and antagonizing apoptosis, which provides a promising therapeutic target for GC treatment and a biomarker for prognosis.

cell biology,biochemistry & molecular biology
An investigation of the molecular characterization of the tripartite motif (TRIM) family and primary validation of TRIM31 in gastric cancer

Yixin Ding,Yangyang Lu,Jing Guo,Shuming Chen,Xiaoxi Han,Shibo Wang,Mengqi Zhang,Rui Wang,Jialin Song,Kongjia Wang,Wensheng Qiu,Weiwei Qi

DOI: https://doi.org/10.1186/s40246-024-00631-7

2024-07-09

Abstract:Most TRIM family members characterized by the E3-ubiquitin ligases, participate in ubiquitination and tumorigenesis. While there is a dearth of a comprehensive investigation for the entire family in gastric cancer (GC). By combining the TCGA and GEO databases, common TRIM family members (TRIMs) were obtained to investigate gene expression, gene mutations, and clinical prognosis. On the basis of TRIMs, a consensus clustering analysis was conducted, and a risk assessment system and prognostic model were developed. Particularly, TRIM31 with clinical prognostic and diagnostic value was chosen for single-gene bioinformatics analysis, in vitro experimental validation, and immunohistochemical analysis of clinical tissue microarrays. The combined dataset consisted of 66 TRIMs, of which 52 were differentially expressed and 43 were differentially prognostic. Significant survival differences existed between the gene clusters obtained by consensus clustering analysis. Using 4 differentially expressed genes identified by multivariate Cox regression and LASSO regression, a risk scoring system was developed. Higher risk scores were associated with a poorer prognosis, suppressive immune cell infiltration, and drug resistance. Transcriptomic data and clinical sample tissue microarrays confirmed that TRIM31 was highly expressed in GC and associated with a poor prognosis. Pathway enrichment analysis, cell migration and colony formation assay, EdU assay, reactive oxygen species (ROS) assay, and mitochondrial membrane potential assay revealed that TRIM31 may be implicated in cell cycle regulation and oxidative stress-related pathways, contribute to gastric carcinogenesis. This study investigated the whole functional and expression profile and a risk score system based on the TRIM family in GC. Further investigation centered around TRIM31 offers insight into the underlying mechanisms of action exhibited by other members of its family in the context of GC.

Figure S7 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Figure S6 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Figure S4 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Figure S2 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Figure S1 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Figure S3 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP

Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma

Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly

TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability

TRIM50 inhibits glycolysis and the malignant progression of gastric cancer by ubiquitinating PGK1

TRIM50 Inhibits Proliferation and Metastasis of Gastric Cancer via Promoting β-Catenin Degradation

TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance

TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1

TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation Via UPP.

STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer

Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition

TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4

TRIM40 interacts with ROCK1 directly and inhibits colorectal cancer cell proliferation through the c-Myc/p21 axis

The E3 ubiquitin ligase TRIM17 promotes gastric cancer survival and progression via controlling BAX stability and antagonizing apoptosis

An investigation of the molecular characterization of the tripartite motif (TRIM) family and primary validation of TRIM31 in gastric cancer